Abstract |
Peanut allergy is a life-threatening, IgE-mediated allergic disease. In developed countries, the prevalence rate of peanut allergy in school-aged children is reported to be in excess of 1% and continues to rise, representing a major public health concern. Peanut allergy is diagnosed on the basis of a relevant clinical history combined with results of skin-prick testing and/or peanut-specific IgE levels. A double-blind placebo-controlled oral food challenge is the gold standard for diagnosis. Currently, there is no approved treatment or disease-modifying therapy for peanut allergy. This review discusses recent advances in molecular diagnostic techniques for peanut allergy and highlights advances in peanut allergy therapeutics, discussing allergen-specific and allergen-nonspecific treatments that are currently in Phase I/II clinical trials.
|
Authors | Saira Z Sheikh, A Wesley Burks |
Journal | Expert review of clinical immunology
(Expert Rev Clin Immunol)
Vol. 9
Issue 6
Pg. 551-60
(Jun 2013)
ISSN: 1744-8409 [Electronic] England |
PMID | 23730885
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Clinical Trials as Topic
- Double-Blind Method
- Humans
- Immunoglobulin E
(immunology)
- Peanut Hypersensitivity
(diagnosis, immunology, pathology, therapy)
- Skin Tests
|